CDTX - Cidara Therapeutics Inc Stock Price, Fair Value and News

11.36USD-0.64 (-5.33%)Delayed as of 17 May 2024, 02:00 pm ET

Market Summary

USD11.36-0.64

Delayedas of 17 May 2024, 02:00 pm

-5.33%

CDTX Stock Price

View Fullscreen

CDTX RSI Chart

CDTX Valuation

Market Cap

54.7M

Price/Earnings (Trailing)

-1.51

Price/Sales (Trailing)

1.18

EV/EBITDA

-0.66

Price/Free Cashflow

-2.94

CDTX Price/Sales (Trailing)

CDTX Profitability

EBT Margin

-83.93%

Return on Equity

203.99%

Return on Assets

-68.8%

Free Cashflow Yield

-34%

CDTX Fundamentals

CDTX Revenue

Revenue (TTM)

46.3M

Rev. Growth (Yr)

-67.58%

Rev. Growth (Qtr)

-51.87%

CDTX Earnings

Earnings (TTM)

-36.3M

Earnings Growth (Yr)

-442.71%

Earnings Growth (Qtr)

-221.38%

Breaking Down CDTX Revenue

52 Week Range

12.00

(Low)(High)

Last 7 days

-4.7%

Last 30 days

-17.7%

Last 90 days

-16.0%

Trailing 12 Months

-55.5%

How does CDTX drawdown profile look like?

CDTX Financial Health

Current Ratio

0.72

CDTX Investor Care

Shares Dilution (1Y)

1.34%

Diluted EPS (TTM)

-7.98

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	46.3M	0	0	0
2023	83.3M	84.6M	56.5M	63.9M
2022	54.4M	27.8M	61.5M	64.4M
2021	11.9M	41.4M	46.1M	49.6M
2020	23.9M	26.8M	10.2M	12.1M
2019	0	0	0	20.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cidara Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	tari leslie	acquired	-	-	111,250	chief scientific officer
Mar 15, 2024	sandison taylor	acquired	-	-	128,750	chief medical officer
Mar 15, 2024	ward shane	acquired	-	-	120,000	coo & clo
Mar 15, 2024	shah preetam	acquired	-	-	108,750	cfo & cbo
Mar 11, 2024	shah preetam	sold	-12,680	0.6698	-18,931	cfo & cbo
Mar 11, 2024	tari leslie	sold	-14,085	0.6698	-21,029	chief scientific officer
Mar 11, 2024	stein jeffrey	sold (taxes)	-39,117	0.69	-56,692	president & ceo
Mar 11, 2024	sandison taylor	sold	-13,839	0.6698	-20,662	chief medical officer
Mar 11, 2024	ward shane	sold	-13,712	0.6698	-20,473	coo & clo
Sep 11, 2023	tari leslie	sold	-17,508	0.948	-18,469	chief scientific officer

Which funds bought or sold CDTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	BVF INC/IL	unchanged	-	864,502	6,312,240	0.17%
May 15, 2024	CITADEL ADVISORS LLC	new	-	77,773	77,773	-%
May 15, 2024	Point72 Asset Management, L.P.	unchanged	-	157,500	1,150,000	-%
May 15, 2024	STATE STREET CORP	reduced	-5.4	21,907	249,814	-%
May 15, 2024	MORGAN STANLEY	reduced	-24.27	-2,005	14,350	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-42.00	-	-%
May 15, 2024	5AM Venture Management, LLC	unchanged	-	142,948	1,043,750	0.23%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-13.06	3,730	507,840	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-27.16	-1,538	8,324	-%
May 15, 2024	Royal Bank of Canada	sold off	-100	-	-	-%

Are Funds Buying or Selling CDTX?

Are funds buying CDTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CDTX

No. of Funds

Unveiling Cidara Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	biotechnology value fund l p	5.4%	4,998,161	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	1.4%	1,250,000	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	1.7%	1,546,745	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	5.4%	3,868,006	SC 13G/A
Feb 14, 2023	nantahala capital management, llc	6.1%	4,367,464	SC 13G/A
Feb 15, 2022	lytton laurence w	2.5%	1,708,328	SC 13G/A
Feb 14, 2022	point72 asset management, l.p.	6.3%	4,200,000	SC 13G/A
Feb 14, 2022	nantahala capital management, llc	7.9%	5,270,458	SC 13G
Feb 14, 2022	omega fund v, l.p.	1.8%	1,249,999	SC 13G/A
Feb 11, 2022	bb biotech ag	0.0%	0	SC 13G/A

Recent SEC filings of Cidara Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 06, 2024	D	D
May 03, 2024	8-K	Current Report
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	4	Insider Trading
Apr 30, 2024	3	Insider Trading
Apr 30, 2024	3	Insider Trading

Peers (Alternatives to Cidara Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Cidara Therapeutics Inc News

Latest updates

Cidara Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	-51.9%	8,463,000	17,583,000	12,718,000	7,497,000	26,107,000	10,219,000	40,744,000	6,216,000	7,269,000	7,225,000	7,076,000	32,863,000	2,408,000	3,729,000	2,416,000	3,392,000	2,530,000	1,815,000	19,100,000
Operating Expenses	-9.9%	19,154,000	21,259,000	22,208,000	21,595,000	23,326,000	23,706,000	26,553,000	21,969,000	25,723,000	23,995,000	25,112,000	22,090,000	20,630,000	25,277,000	19,945,000	21,603,000	17,091,000	15,895,000	16,072,000
S&GA Expenses	11.0%	5,998,000	5,405,000	4,432,000	4,039,000	4,457,000	3,595,000	6,270,000	5,339,000	5,342,000	4,982,000	4,607,000	4,370,000	4,781,000	4,148,000	3,687,000	3,969,000	4,095,000	4,405,000	4,573,000
R&D Expenses	-21.2%	11,593,000	14,718,000	17,389,000	17,556,000	18,869,000	20,111,000	20,283,000	16,630,000	20,381,000	19,013,000	20,505,000	17,720,000	15,849,000	21,129,000	16,258,000	17,634,000	12,996,000	11,490,000	11,499,000
EBITDA Margin	-38.1%	-0.84	-0.61	-0.38	-0.33	-0.40	-0.51	-0.69	-1.52	-0.77	-0.85	-1.55	-1.73	-5.98	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	2,000	13,000	25,000	38,000	51,000	64,000	75,000	88,000	102,000	116,000	139,000	144,000	157,000
Income Taxes	-100.0%	-	64,000	230,000	149,000	-	272,000	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-3,149,000	-8,877,000	-13,475,000	-	-13,325,000	14,246,000	-15,759,000	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-38.1%	-0.84	-0.61	-0.38	-0.33	-0.40	-0.52	-0.69	-1.53	-0.78	-0.86	-1.57	-1.74	-6.04	-	-	-	-	-	-
Net Income	-221.4%	-10,326,000	-3,213,000	-9,107,000	-13,624,000	3,013,000	-13,597,000	14,246,000	-15,759,000	-18,474,000	-16,803,000	-18,083,000	10,711,000	-18,292,000	-21,634,000	-17,632,000	-18,306,000	-14,539,000	-14,023,000	3,039,000
Net Income Margin	-118.5%	-0.78	-0.36	-0.59	-0.12	-0.15	-0.52	-0.60	-2.49	-0.78	-0.86	-1.03	-1.13	-6.35	-	-	-	-	-	-
Free Cashflow	48.3%	-6,667,000	-12,900,000	-1,760,000	2,715,000	-10,992,000	-21,011,000	27,964,000	-11,852,000	-23,692,000	-14,907,000	-11,984,000	3,423,000	-1,805,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-21.4%	53.00	67.00	64.00	68.00	82.00	47.00	67.00	39.00	55.00	75.00	51.00	64.00	54.00	60.00	64.00	73.00	84.00	69.00	82.00	52.00	64.00
Current Assets	-23.0%	47.00	61.00	58.00	63.00	80.00	45.00	64.00	37.00	52.00	72.00	47.00	61.00	51.00	57.00	60.00	70.00	81.00	66.00	77.00	48.00	60.00
Cash Equivalents	-18.9%	29.00	36.00	49.00	50.00	48.00	33.00	53.00	25.00	36.00	62.00	40.00	53.00	49.00	43.00	54.00	64.00	74.00	60.00	74.00	45.00	57.00
Inventory	19.2%	7.00	6.00	3.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.1%	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00
Liabilities	-6.3%	70.00	75.00	70.00	66.00	67.00	62.00	69.00	58.00	59.00	54.00	52.00	48.00	52.00	50.00	34.00	32.00	30.00	31.00	33.00	20.00	20.00
Current Liabilities	-3.0%	65.00	67.00	50.00	45.00	47.00	41.00	44.00	42.00	41.00	34.00	33.00	34.00	40.00	39.00	34.00	32.00	30.00	30.00	32.00	19.00	19.00
Shareholder's Equity	-116.6%	-17.78	-8.21	8.00	2.00	15.00	-14.44	9.00	-18.54	5.00	13.00	-	16.00	2.00	11.00	30.00	41.00	54.00	38.00	49.00	32.00	44.00
Retained Earnings	-2.3%	-451	-441	-438	-429	-415	-418	-404	-419	-403	-377	-360	-342	-353	-334	-313	-295	-277	-259	-245	-248	-235
Additional Paid-In Capital	0.2%	434	433	432	432	431	404	403	401	400	399	359	358	355	345	343	337	331	298	295	281	279
Shares Outstanding	0.7%	5.00	5.00	5.00	5.00	5.00	4.00	4.00	3.00	3.00	3.00	2.00	2.00	2.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	100	-	-	-	33.00	-	-	-	98.00	-	-	-	151	-	-	-	44.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	47.8%	-6,644	-12,722	-1,634	2,822	-10,898	-21,002	27,973	-11,836	-23,608	-14,907	-11,972	3,440	-1,793	-11,128	-14,083	-14,072	-15,128	-15,197	16,619	-12,808	-17,146
Share Based Compensation	-4.2%	795	830	796	795	640	673	843	678	1,338	1,363	901	871	879	847	1,002	995	1,246	1,023	1,509	1,257	1,284
Cashflow From Investing	87.1%	-23.00	-178	-126	-107	-94.00	-9.00	-9.00	-16.00	-84.00	-	-12.00	-17.00	-12.00	-	-54.00	-96.00	-36.00	-	-	-26.00	-9.00
Cashflow From Financing	-1262.5%	-93.00	8.00	-	-261	26,237	664	107	-1,111	-611	36,875	-810	887	7,645	409	3,720	3,939	29,210	1,641	12,632	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CDTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Collaboration revenue	$ 5,637	$ 26,107
Product revenue	$ 2,826	$ 0
Product revenue [Extensible Enumeration]	Product [Member]	Product [Member]
Total revenues	$ 8,463	$ 26,107
Operating expenses:
Cost of product revenue	1,563	0
Research and development	11,593	18,869
Selling, general and administrative	5,998	4,457
Total operating expenses	19,154	23,326
Income (loss) from operations	(10,691)	2,781
Other income, net:
Interest income, net	365	232
Total other income, net	365	232
Net income (loss) and comprehensive income (loss)	(10,326)	3,013
Net income (loss) and comprehensive income (loss)	(10,326)	3,013
Allocation of earnings to participating securities	0	(636)
Net income (loss) attributable to common stockholders	$ (10,326)	$ 2,377
Basic net earnings (loss) per common share (in dollars per share)	$ (2.28)	$ 0.60
Diluted net earnings (loss) per common share (in dollars per share)	$ (2.28)	$ 0.60
Shares used to compute basic net earnings (loss) per common share (in shares)	4,537,782	3,932,050
Shares used to compute diluted net earnings (loss) per common share (in shares)	4,537,782	5,059,514

CDTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 29,018	$ 35,778
Accounts receivable	7,281	16,246
Inventory	7,269	6,097
Prepaid expenses and other current assets	3,266	2,734
Total current assets	46,834	60,855
Property and equipment, net	534	557
Finance lease right-of-use asset, net	762	782
Operating lease right-of-use asset	3,599	3,788
Other assets	987	1,048
Total assets	52,716	67,030
Current liabilities:
Accounts payable	5,055	3,772
Accrued liabilities	8,241	14,177
Accrued indirect tax liabilities	20,618	18,040
Accrued compensation and benefits	5,723	5,034
Current contract liabilities	24,324	25,095
Current portion of finance lease liability	249	218
Current portion of operating lease liability	1,215	1,082
Total current liabilities	65,425	67,418
Long-term contract liabilities	1,888	4,245
Long-term finance lease liability	510	575
Long-term operating lease liability	2,673	3,002
Total liabilities	70,496	75,240
Commitments and contingencies
Stockholders’ deficit:
Preferred stock
Common stock, $0.0001 par value; 20,000,000 shares authorized at March 31, 2024 and December 31, 2023; 4,561,696 shares issued and outstanding at March 31, 2024 and 4,530,113 shares issued and outstanding at December 31, 2023	1	1
Additional paid-in capital	433,976	433,220
Accumulated deficit	(451,757)	(441,431)
Total stockholders’ deficit	(17,780)	(8,210)
Total liabilities and stockholders’ deficit	52,716	67,030
Series X Convertible Preferred Stock
Stockholders’ deficit:
Preferred stock	$ 0	$ 0

About Cidara Therapeutics Inc

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CEO	Dr. Jeffrey L. Stein Ph.D.
WEBSITE	cidara.com
INDUSTRY	Biotechnology
EMPLOYEES	73

Cidara Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Cidara Therapeutics Inc? What does CDTX stand for in stocks?

CDTX is the stock ticker symbol of Cidara Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cidara Therapeutics Inc (CDTX)?

As of Thu May 16 2024, market cap of Cidara Therapeutics Inc is 54.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDTX stock?

You can check CDTX's fair value in chart for subscribers.

What is the fair value of CDTX stock?

You can check CDTX's fair value in chart for subscribers. The fair value of Cidara Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cidara Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cidara Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CDTX is over valued or under valued. Whether Cidara Therapeutics Inc is cheap or expensive depends on the assumptions which impact Cidara Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDTX.

What is Cidara Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, CDTX's PE ratio (Price to Earnings) is -1.51 and Price to Sales (PS) ratio is 1.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDTX PE ratio will change depending on the future growth rate expectations of investors.